Theravance Biopharma (TBPH) Share-based Compensation (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Share-based Compensation data on file, last reported at $4.5 million in Q1 2026.

• On a quarterly basis, Share-based Compensation rose 415.33% year-over-year to $4.5 million in Q1 2026; TTM through Mar 2026 was $22.1 million, a 29.74% increase from a year earlier, with the FY2025 full-year figure at $18.5 million, down 28.25% from the prior year.
• Share-based Compensation for Q1 2026 stood at $4.5 million, down from $16.4 million in the prior quarter.
• Over the last five years, Share-based Compensation for TBPH reached as high as $16.4 million in Q4 2025 and fell as low as -$17.0 million in Q4 2023.
• Historically, Share-based Compensation has averaged $4.7 million across 5 years, with a median of $5.8 million in 2024.
• Across the five-year window, Share-based Compensation tumbled 345.28% in 2023 and jumped 489.52% in 2024, its largest moves.
• Year by year, Share-based Compensation stood at $7.0 million in 2022, then tumbled by 345.28% to -$17.0 million in 2023, then soared by 134.18% to $5.8 million in 2024, then soared by 181.86% to $16.4 million in 2025, then slumped by 72.57% to $4.5 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $4.5 million in Q1 2026, $16.4 million in Q4 2025, and -$7.4 million in Q3 2025.